Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTONIO: perioperative/adjuvant atezolizumab in MSI-high or dMMR stage II high-risk or stage III colorectal cancer in patients ineligible for oxaliplatin
2024-515224-37-00Phase 2Authorised
- Sponsor
- AIO-Studien
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and IMM-101 in colorectal cancer (CRC) (2 arms), sponsored by AIO-Studien. Primary endpoints: Disease-free survival rate at 3 years, Pathological complete or subtotal regression and 1 more. Planned start Aug 2024; status: authorised.
02
Drugs
atezolizumabIMM-101
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-515224-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515224-37-00.